Interleukin-17: Friend or foe in organ fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Fibrosis affects all vital organs accounting for a staggering 45% of deaths worldwide and no effective therapies are currently available. Unresolved inflammation triggers downstream signaling events that lead to organ fibrosis. In recent years, proinflammatory cytokine Interleukin-17 (IL-17) has been implicated in several chronic inflammatory diseases that often culminate in organ damage followed by impaired wound healing and fibrosis. In this review, we outline the contribution of the IL-17 in mediating fibrotic diseases in various organs. A comprehensive understanding of the inflammatory events, and particularly the details of IL-17 signaling in vivo, could be beneficial in designing new therapeutic or preventive approaches to treat fibrosis. Additionally, understanding organ-specific differences in IL-17 activity could lead to targeted therapies and help spare other organs from unwanted side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 4×
“Gene products induced by IL-17 include cytokines (IL-6, GM-CSF, TNFα), chemokines (CXCL1, CXCL2, CCL20) and inflammatory effectors (acute-phase proteins, complement), all of which can act as profibrotic factors in organ fibrosis [3, 21].”
BackgroundInfluentialLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056 · cited 5×
“It has also been shown to appear without any underlying cause, termed as idiopathic pulmonary fibrosis (IPF) [31].”
BackgroundInfluentialPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 5×
“In contrast, under inflammatory settings where IFN-γ (Th1 cytokine) dominates, organ fibrosis is attenuated [2, 17, 18].”
BackgroundInfluentialThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 1×
“HSC is a highly regulated process involving multiple cytokines and growth factors produced by liver infiltrating immune cells and hepatic cells [64, 65].”
BackgroundHepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
A protective function for interleukin 17A in T cell–mediated intestinal inflammation
O'Connor Jr, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K., & Flavell, R. A. (2009) · Nature Immunology · doi:10.1038/ni.1736 · Cited by 756
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Cited by
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979
The senescence-associated secretory phenotype and its physiological and pathological implications
Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00727-x · Cited by 948
Targeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
Metadata
- Authors
- Ramani, K., & Biswas, P. S.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 120
- Pages
- 282-288
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2911411032
- Cited by
- 66
- References
- 21
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-17: Friend or foe in organ fibrosis. https://app.cochat.ai/papers/10.1016/j.cyto.2018.11.003
- The paper
- Ramani, K., & Biswas, P. S. (2019). Interleukin-17: Friend or foe in organ fibrosis. Cytokine. https://doi.org/10.1016/j.cyto.2018.11.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.